Clinical Edge Journal Scan

Pregnant women with RA and their infants at risk for adverse outcomes and rehospitalization


 

Key clinical point: Pregnant women with vs without rheumatoid arthritis (RA) and their infants should be closely monitored prenatally and during the year after delivery as they are at a higher risk for rehospitalization within 2 years and more likely to require intensive prenatal or neonatal care.

Major finding: Women with vs without RA required more intensive prenatal care (adjusted relative risk [aRR] 1.46; 95% CI 1.33-1.60) and had a higher risk for postpartum non-pregnancy rehospitalization <2 years after delivery (aRR 1.33; 95% CI 1.13-1.56). Infants of women with vs without RA had a higher risk for neonatal intensive care unit admission (aRR 1.89; 95% CI 1.56-2.30) and rehospitalization <2 years after birth (aRR 1.22; 95% CI 1.01-1.46).

Study details: This population-based retrospective cohort study included pregnant women with (n = 1223) and without (n = 12,293) RA and those with (n = 1354) and without (n = 13,751) systemic lupus erythematosus.

Disclosures: This study was funded by Eunice Kennedy Shriver National Institute of Child Health & Human Development, US National Institutes of Health. The authors did not report conflicts of interest.

Source: Singh N et al. Birth outcomes and re-hospitalizations among pregnant women with rheumatoid arthritis and systemic lupus erythematosus and their offspring. Arthritis Care Res (Hoboken) . 2023 (Jan 10). Doi: 10.1002/acr.25087

Recommended Reading

First Humira biosimilar launches in U.S.
MDedge Rheumatology
Commentary: Glucocorticoid use and progression in RA, February 2023
MDedge Rheumatology
Systemic sclerosis antibodies show link to interstitial lung disease in RA
MDedge Rheumatology
Prehospital COVID therapy effective in rheumatic disease patients
MDedge Rheumatology
UnitedHealthcare tried to deny coverage to a chronically ill patient. He fought back, exposing the insurer’s inner workings.
MDedge Rheumatology
Biosimilars perform identically to originator biologics in natural experiment
MDedge Rheumatology
Health plans get very poor scores for access to autoimmune drugs
MDedge Rheumatology
Sarilumab shows long-term safety and efficacy in RA
MDedge Rheumatology
Concomitant methotrexate-glucocorticoid raises bacterial infection risk in RA patients taking bDMARD
MDedge Rheumatology
Treat-to-target management improves cardiovascular outcomes in early RA
MDedge Rheumatology